2016’s Worst Clinical Trial Failures

December 23, 2016

(Managed Care Magazine) – Several costly trial failures have made 2016 a depressing year for drug makers, according to Motley Fool analyst Cory Renauer. Bristol-Myers Squibb, Juno Therapeutics, Celldex Therapeutics, and Clovis Oncology all learned how hard it is to score a touchdown in the oncology game. Eli Lilly and Biogen, too, stubbed their toes with failed neurology drugs. Renauer reviewed seven initially promising medications that ultimately delivered nothing but heartbreak to their developers.

Recommended Reading